A detailed history of Exodus Point Capital Management, LP transactions in Veracyte, Inc. stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 734,448 shares of VCYT stock, worth $28.8 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
734,448
Previous 798,641 8.04%
Holding current value
$28.8 Million
Previous $17.3 Million 44.46%
% of portfolio
0.15%
Previous 0.12%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$21.0 - $35.25 $1.35 Million - $2.26 Million
-64,193 Reduced 8.04%
734,448 $25 Million
Q2 2024

Aug 13, 2024

BUY
$18.86 - $23.55 $12.3 Million - $15.3 Million
650,646 Added 439.64%
798,641 $17.3 Million
Q1 2024

May 14, 2024

BUY
$21.0 - $29.1 $2.29 Million - $3.17 Million
109,056 Added 280.07%
147,995 $3.28 Million
Q3 2023

Nov 09, 2023

BUY
$22.33 - $29.92 $240,695 - $322,507
10,779 Added 38.28%
38,939 $870,000
Q2 2023

Aug 10, 2023

BUY
$20.96 - $26.99 $369,524 - $475,833
17,630 Added 167.43%
28,160 $717,000
Q1 2023

May 11, 2023

SELL
$20.58 - $27.89 $869,258 - $1.18 Million
-42,238 Reduced 80.04%
10,530 $235,000
Q4 2022

Feb 13, 2023

BUY
$15.31 - $29.94 $807,878 - $1.58 Million
52,768 New
52,768 $1.25 Million
Q4 2021

Feb 11, 2022

SELL
$36.09 - $53.79 $323,077 - $481,528
-8,952 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$35.62 - $52.97 $580,214 - $862,828
-16,289 Reduced 64.53%
8,952 $416,000
Q2 2021

Aug 16, 2021

BUY
$32.94 - $56.62 $831,438 - $1.43 Million
25,241 New
25,241 $1.01 Million
Q1 2021

May 17, 2021

SELL
$44.47 - $81.38 $159,558 - $291,991
-3,588 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$32.49 - $61.88 $116,574 - $222,025
3,588 New
3,588 $176,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $2.81B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.